Studiet var ikke dimensioneret til at vise en reduktion i kliniske frakturer hos mænd; incidensen af kliniske frakturer var 7, 5% hos mænd behandlet med Aclasta i forhold til 8, 7% for placebo.
The study was not powered to show a reduction in clinical fractures in men; the incidence of clinical fractures was 7.5% in men treated with Aclasta versus 8.7% for placebo.